Komori
Treasury Stock4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

From 1 July 2026 to 31 July 2026, the company acquired 90,600 treasury shares for approximately ¥286 million. Cumulative acquisitions based on resolutions of the Board of Directors totaled 186,500 shares for approximately ¥604 million.

Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
286404500
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange

Resolved 30 March 2026 / Acquisition period 18 May 2026–18 December 2026

35.2%
Cumulative utilization rate
Limit343,500 株 remaining
Number of Shares530,000 shares (maximum)
30.2%
Cumulative utilization rate
LimitShares 35.2%1,396,435,000 円 remaining
Amount¥2,000,000,000 (maximum)

The darker band is the portion acquired this time (1 July 2026–31 July 2026 (on a contract-settlement basis)). At this pace, the share-count limit will be reached first, and the acquisition will end without using the full monetary limit.

Number of Shares
Limit530,000 shares (maximum)
Cumulative total186,500 shares (as of 31 July 2026)
Current90,600 shares
Amount
Limit¥2,000,000,000 (maximum)
Cumulative total¥603,565,000 (as of 31 July 2026)
Current¥286,404,500
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Average acquisition price for this transaction (calculated)¥3,161 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction90,600 shares
Total current acquisition price¥286,404,500
Acquisition date/acquisition period1 July 2026–31 July 2026 (on a contract-settlement basis)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired186,500 shares (as of 31 July 2026)
Cumulative acquisition cost¥603,565,000 (as of 31 July 2026)
Resolution date30 March 2026
Maximum number of shares to be acquired530,000 shares (maximum)
Total acquisition price¥2,000,000,000 (maximum)
Acquisition period under the resolution18 May 2026–18 December 2026
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company is reporting the status of treasury share acquisitions based on a resolution of the Board of Directors, pursuant to provisions in its articles of incorporation established under Article 165, paragraph 2 of the Companies Act. The company also states that some or all of the planned acquisitions may not be completed depending on market conditions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori